Vaxcyte Inc. Common Stock (PCVX)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a business that earns money and can be valued on proven earnings. Vaxcyte fails that test today. In fiscal 2025, the year ended 2025-12-31, it reported a net loss of $766.6 million and diluted EPS of -$5.63. In fiscal 2024 it lost $463.9 million, or -$3.80 per share, and in fiscal 2023 it lost $402.3 million, or -$4.14. The deterioration continued into fiscal 2026: the quarter ended 2026-06-30 showed a net loss of $284.3 million, or -$1.97 per share, after a $320.6 million loss in the quarter ended 2026-03-31. Those are not the marks of a mature moat; they are the marks of a research effort consuming capital. Trailing free cash flow was -$921.1 million, a -9.3% FCF yield on the $9.9 billion market cap as of the 2026-10-13 close. The balance sheet has low leverage, with D/E of 0.04, and the Altman Z-Score of 14.95 suggests near-term solvency is not the issue. But Piotroski is 0/9 and ROE is -36.51%, so capital is being burned, not compounded. The stock's $66.80 price and 3.51 price-to-book ratio, both FairStock calculations, are not grounded in current earnings or revenue. FairStock's P/E is -8.75 and no Lynch category fits because of four straight loss years. A vaccine platform could someday produce large profits, but today I see a speculative clinical-stage story, not a Graham bargain. Without revenue, profits, or a margin of safety, the price depends on future trial outcomes I cannot underwrite from these figures.

In plain English: Vaxcyte is a clinical-stage vaccine company: it is still testing its main products and has no reported sales yet. The business looks weak on current numbers because it keeps losing money and burning cash, with no profits. At $66.80 on 2026-10-13, the price looks expensive compared with those current results because the value depends on future vaccine success, not money the company is making today.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer